Drug intelligence / Profile preview

SGN2

Development stage: Preclinical
Lead developer: Guangzhou Sinogen Pharmaceutical
Modality: Oncolytic Bacteria → Oncolytic Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Intravenous

Overview

SGN2 is an engineered oncolytic bacterial therapy developed by Guangzhou Sinogen Pharmaceutical (also known as Huajin Pharmaceutical Technology). It utilizes an attenuated strain of *Salmonella typhimurium* as a vector to deliver and express the enzyme L-methioninase directly within the tumor microenvironment. This approach exploits the 'Hoffman effect,' where many cancer cells exhibit an absolute requirement for the amino acid methionine. By enzymatically depleting methionine, SGN2 induces metabolic stress, inhibits protein synthesis, and promotes apoptosis in solid tumors. The therapy is designed for systemic administration via intravenous injection and is currently in early-stage development for various solid malignancies.

Beyond the preview

Go deeper on SGN2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SGN2.

Explore the full profile